Xemperia

Description

Xemperia develops blood-based diagnostic tests that detect cancer-associated biomarkers using multiomics and AI methods, and creates DNA-based nanosensors for rapid, sensitive detection of RNA/DNA for cancer detection and monitoring.

Related

• AMADIXAMADIX develops blood-based liquid biopsy tests and machine-learning software that analyze molecular biomarkers and clinical data to detect…
• Age LabsAge Labs develops biomarkers and predictive algorithms for early detection of age-related diseases, offering diagnostic tests, biological…
• Cyted HealthCyted Health combines minimally invasive cell collection with molecular analysis to build diagnostic tests (EndoSign®) for earlier…
• ADmit THERAPEUTICSADmit THERAPEUTICS develops and commercializes MAP-AD®, an in vitro diagnostic test using mitochondrial DNA epigenetic biomarkers, NGS and…
• AltraTechAltraTech builds a multimodal molecular diagnostic platform and portable digital diagnostic device that detects and quantifies DNA, RNA,…
• DiaxxoDiaxxo provides a point-of-care PCR testing platform using diaxxoPCR devices and reagent-loaded diaxxoPod cartridges to run rapid real-time…
• IRUBISIRUBIS provides Monipa, a plug-and-play inline monitoring tool for downstream mAb and DNA/RNA bioprocesses that uses a mid-infrared…
• UpFront DiagnosticsUpFront Diagnostics develops a portable rapid blood test that detects stroke biomarkers GFAP and others, delivering clinically validated…
• Jizô AIJizô AI provides a network detection and response (NDR) platform delivering visibility, intelligent detection, rapid investigation and…